- Dosage must be sufficient, typically in the 60-80 mg range, but some patients require more. In no other branch of medicine can one imagine guidelines — much less regulations — that insist on the lowest possible dosage, even if that dosage is only marginally effective in saturating the receptors. No medicine can work unless given in adequate dosage, so low-dosage programs are self-defeating. In the United States, the General Accounting Office compared the effectiveness of methadone programs across the country; the least successful were those with the lowest doses.
- Duration of treatment must be adequate. In no other branch of medicine would effective therapy for a chronic disease be terminated after a fixed time. Imagine the outcry if physicians were forced to discontinue steroids and nonsteroidal anti-inflammatory drugs for rheumatoid arthritis, or digoxin for congestive heart failure. Yet some jurisdictions have mandated a time limit on methadone maintenance. Especially ironic is the view that when addicts are doing WELL on methadone, they should be terminated; one would think the opposite made more sense — that patients doing well on a drug should stay on that drug.
- Patients themselves are usually eager to quit methadone — not only because of the nuisance but also because societal attitudes make them feel demeaned. Staff should DISCOURAGE terminating methadone until fully satisfactory social rehabilitation has been achieved and no heroin whatsoever has been used for at least a year. However, if a patient does terminate prematurely and then relapses, the door should be left open for immediate readmission and re-induction without punitive attitudes on the part of treatment staff.
- Urine testing is essential — on site, with immediate feedback of results as an aid to the counseling process. Again, consider the treatment of other diseases. Would we treat hypertension without regularly checking the blood pressure? Or obesity without regular weighings? Especially with a patient population not famous for veracity, OBJECTIVE EVIDENCE provides the only sure milestones for measuring progress or detecting relapses.

AATOD...Follow Us 💫
National Organization Expanding Access to Quality Opioid Use Disorder Treatment Services Since 1984 #morethanmedicine #OUD

✨ We’re excited to share #AATOD2025 post-conference resources!
Whether you joined us in person or couldn’t attend this year, you can still access the full conference experience.
🎥 Post-Conference Recording Order Form
➡️ Please DOWNLOAD the order form for full conference access, bit.ly/3NxXF0M.
📌 Continuing Education credits are available to in-person attendees only.
3 months ago


We encourage you to register for the virtual webinar sponsored by NYU Langone Health Center for Opioid Epidemiology & Policy and Center for Alcohol & Addiction Studies.
TOPIC ➡️ Challenges and Opportunities for Implementing Mobile Methadone Units: Lessons from Four U.S. States
REGISTER ➡️ bit.ly/3NEBE0a
3 months ago

⏳ STILL TIME - STILL TUESDAY
Patient access to OTPs saves lives every day.
For this #GIVINGTUESDAY, please consider making a tax-deductible gift to the American Association for the Treatment of Opioid Dependence. AATOD is dedicated to expanding access to quality Opioid Use Disorder treatment services, which has been our hallmark since 1984.
AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. Please support AATOD's mission by making an online donation.
DONATE: www.aatod.org/give/donate-online/
5 months ago

‼️WEBINAR ALERT
There’s still time to REGISTER for tomorrow’s (11/12) complimentary CJ webinar ➡️ bit.ly/49Lilez.
Expanding Access to Medication Assisted Treatment in Jails and Prisons.
▪️Moderator:
Mark W. Parrino, MPA will moderate the session as the President of the American Association for the Treatment of Opioid Dependence (AATOD).
▪️Presenters:
Paul N. Samuels
(Director/President, Legal Action Center) will provide an understanding of broad developments in this area, including court rulings.
▪️Brandi Harrison, BSW, MS, CCHP
(Project Manager, Justice Collaborations, Allegheny County Department of Human Services) will also discuss the opening of a treatment program in the Alleghny County Jail in Pennsylvania.
There will be ample time for Q&A, and this webinar will become available to the public for On-Demand viewing via the AATOD website.
5 months ago
#aatod2025 comes to an end!
Up Next: #aatod2027 - Spring 2027, Georgia.
6 months ago
#aatod2025 comes to an end!
Up Next: #aatod2027 - Spring 2027, Georgia.
6 months ago

See you this evening at the AATOD Open Board Meeting. #aatod2025 #theevolvingfieldofopioidtreatment
7 months ago

🗞️ Press Release #aatod2025
33 Workshops, 3 Plenary Sessions, Special Pre-Conference Sessions, Exhibits, Awards, Clinic Tours and More! https://prn.to/46RPQsT.
7 months ago

📆 #aatod2025 is just days away.
We are releasing a video message from our Conference Chair who is extending a warm invitation to Philadelphia and providing details about registering as an attendee or volunteer, or both.
REGISTER ➡️www.aatodconference.com.
#theevolvingfieldofopioidtreatment
7 months ago
The Evolving Field of Opioid Treatment
AATOD proudly presented the world’s premier training conference event for the treatment of Opioid Use Disorder.
#aatod2025 Conference Countdown
AATOD, Inc.
39 Broadway, Suite E26
New York, New York 10006
Contact Us
Phone
: 212-566-5555
Email
: info@aatod.org
Social Sharing
OPIOID EDUCATION
Stay Connected to AATOD










